SXTP Stock Forecast & Price Target

60 Degrees is expected to experience continued revenue growth in FY26 due to increased sales of ARAKODA and potential launch of dietary supplement extracted from Australian Chestnuts. Additionally, the recent ATM financing and partnership deals for improved affordability and patient access indicate a positive outlook for the company. However, low visibility on regulatory approval and potential dilution from future capital raises are risks to be considered.

60 Degrees is facing challenges in drug development and commercialization as its balance sheet remains weak, leading to uncertainty and lack of visibility in its clinical development plans. The company's financial constraints and potential for dilutive raises may hinder its ability to successfully execute clinical trials. The recent submission for a non-Rx product represents a new opportunity but may not be enough to offset the negative outlook caused by ongoing financial struggles and lack of pipeline visibility.